- Home
- RETO vs MYNZ Comparison
RETO vs MYNZ Comparison
Compare RETO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RETO
- MYNZ
- Stock Information
- Founded
- RETO 1999
- MYNZ 2021
- Country
- RETO China
- MYNZ Germany
- Employees
- RETO N/A
- MYNZ N/A
- Industry
- RETO Multi-Sector Companies
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- RETO Consumer Discretionary
- MYNZ Health Care
- Exchange
- RETO Nasdaq
- MYNZ Nasdaq
- Market Cap
- RETO 7.3M
- MYNZ 7.9M
- IPO Year
- RETO 2017
- MYNZ 2021
- Fundamental
- Price
- RETO $2.57
- MYNZ $0.94
- Analyst Decision
- RETO
- MYNZ Buy
- Analyst Count
- RETO 0
- MYNZ 2
- Target Price
- RETO N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- RETO 18.2K
- MYNZ 910.4K
- Earning Date
- RETO 05-05-2026
- MYNZ 12-29-2025
- Dividend Yield
- RETO N/A
- MYNZ N/A
- EPS Growth
- RETO N/A
- MYNZ N/A
- EPS
- RETO N/A
- MYNZ N/A
- Revenue
- RETO $2,109,956.00
- MYNZ $659,935.00
- Revenue This Year
- RETO N/A
- MYNZ N/A
- Revenue Next Year
- RETO N/A
- MYNZ $5.03
- P/E Ratio
- RETO N/A
- MYNZ N/A
- Revenue Growth
- RETO 16864.81
- MYNZ N/A
- 52 Week Low
- RETO $2.50
- MYNZ $0.92
- 52 Week High
- RETO $61.50
- MYNZ $10.56
- Technical
- Relative Strength Index (RSI)
- RETO 56.51
- MYNZ 25.19
- Support Level
- RETO $2.66
- MYNZ $1.00
- Resistance Level
- RETO $2.86
- MYNZ $2.09
- Average True Range (ATR)
- RETO 0.19
- MYNZ 0.20
- MACD
- RETO -0.05
- MYNZ -0.04
- Stochastic Oscillator
- RETO 11.48
- MYNZ 3.55
About RETO ReTo Eco-Solutions Inc.
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Machinery and Equipment sales, and Technology Consulting and other services. The company earns its revenue from the Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.